Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, a brain metastases imaging agent that demonstrated 93% concordance with MRI. The company is preparing to initiate a pivotal Phase 3 trial in 1Q27 and has secured a manufacturing partnership with Siemens Healthineers. Additionally, Radiopharm reported positive Phase 1 imaging data for RAD301 in pancreatic cancer and advanced RAD202 to the fourth dosing cohort in its HER2+ solid tumor study.